219 related articles for article (PubMed ID: 33605496)
1. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer.
Fujii A; Masuda T; Iwata M; Tobo T; Wakiyama H; Koike K; Kosai K; Nakano T; Kuramitsu S; Kitagawa A; Sato K; Kouyama Y; Shimizu D; Matsumoto Y; Utsunomiya T; Ohtsuka T; Yamanishi Y; Nakamura M; Mimori K
Cancer Sci; 2021 Apr; 112(4):1655-1668. PubMed ID: 33605496
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
3. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
4. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
5. Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis.
Sun Y; Ma J; Lin J; Sun D; Song P; Shi L; Li H; Wang R; Wang Z; Liu S
Anticancer Drugs; 2021 Oct; 32(9):950-961. PubMed ID: 34016832
[TBL] [Abstract][Full Text] [Related]
6. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
7. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
8. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
9. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
Yoshimachi S; Shirakawa R; Cao M; Trinh DA; Gao P; Sakata N; Miyazaki K; Goto K; Miura T; Ariake K; Maeda S; Masuda K; Ishida M; Ohtsuka H; Unno M; Horiuchi H
Cancer Sci; 2021 Aug; 112(8):3064-3073. PubMed ID: 34009715
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
12. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
13. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
14. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of gene expression profiles reveals specific signaling pathways associated with pancreatic duct adenocarcinoma.
Li J; Tan W; Peng L; Zhang J; Huang X; Cui Q; Zheng J; Tan W; Wu C; Lin D
Cancer Commun (Lond); 2018 Apr; 38(1):13. PubMed ID: 29764514
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between hypoxia-sensing ULK1/2 and YAP-driven glycolysis fuels pancreatic ductal adenocarcinoma development.
Jia Y; Li HY; Wang Y; Wang J; Zhu JW; Wei YY; Lou L; Chen X; Mo SJ
Int J Biol Sci; 2021; 17(11):2772-2794. PubMed ID: 34345207
[TBL] [Abstract][Full Text] [Related]
18. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
19. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin
Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J
Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
